Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919479 | 0.93 | CDK2 (0.45) | CDK2KCNH2CDK4CDKL1CDK1 | |
| SCHEMBL1918780 | 0.85 | HDAC1 (0.40) | CDK2KCNH2 | |
| SCHEMBL9910029 | 0.85 | CDK2 (0.38) | CDK2KCNH2 | |
| SCHEMBL2699027 | 0.83 | HDAC1 (0.40) | CDK2KCNH2CDK4CDKL1 | |
| SCHEMBL2697278 | 0.82 | HDAC1 (0.39) | CDK2KCNH2 | |
| SCHEMBL9910031 | 0.81 | CDK2 (0.35) | CDK2KCNH2CDK4CDK1 | |
| SCHEMBL3354545 | 0.78 | HDAC6 (0.36) | — | |
| SCHEMBL659119 | 0.76 | CDK2 (0.54) | CDK2KCNH2CDK4CDKL1CDK1 | |
| SCHEMBL9910027 | 0.76 | GRM1 (0.43) | — | |
| SCHEMBL9910030 | 0.75 | MAPT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CDK2 213/4885KCNH2 4061/4885CDK4 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.